United States· US:0003-2188_962695b7-21f5-44bb-80e0-cb3b48c80be6
ORENCIA
A abatacept product containing abatacept, registered in United States by E.R. Squibb & Sons, L.L.C.. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Abatacept is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AA24 (abatacept), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Abatacept · ATC L04AA24
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of abatacept costs, country by country.
Normalised to the WHO defined daily dose (27 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Abatacept · price per daily dose (27 mg)
USD · FX 28 Sept 2026
- CH Switzerland$59.45
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ABATACEPT
- Manufacturer
- E.R. Squibb & Sons, L.L.C.
- Country
- United States (US)
- ATC code
- L04AA24
- ATC class
- Abatacept
- Defined daily dose
- 27 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 8
- ndc1100032188114 SYRINGE, GLASS in 1 CARTON (0003-2188-11) / 1 mL in 1 SYRINGE, GLASS
- ndc1100032188514 SYRINGE, GLASS in 1 CARTON (0003-2188-51) / 1 mL in 1 SYRINGE, GLASS
- ndc1100032188901 SYRINGE, GLASS in 1 CARTON (0003-2188-90) / 1 mL in 1 SYRINGE, GLASS
- ndc1100032188911 SYRINGE, GLASS in 1 CARTON (0003-2188-91) / 1 mL in 1 SYRINGE, GLASS
- ndc110003-2188-11
- ndc110003-2188-51
- ndc110003-2188-90
- ndc110003-2188-91
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
63 interactions on record for abatacept.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Abatacept · interactions on record
63 records
- 30 severe
- 26 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Abatacept in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaORENCIABristol-Myers Squibb Pharma EEIG, Dublin
- FinlandOrenciaBristol-Myers Squibb Pharma EEIG
- BelgiumOrencia 125 mgBristol-Myers Squibb Pharma
- FranceORENCIA 125 mg, solution injectable en seringue préremplieBRISTOL-MYERS SQUIBB PHARMA (IRLANDE)
- United KingdomOrencia 125mg/1ml solution for injection pre-filled syringesBristol-Myers Squibb Pharmaceuticals Ltd
- IrelandOrencia 125 mg solution for injection in pre-filled penBristol-Myers Squibb Pharma EEIG
- IcelandOrenciaBristol-Myers Squibb Pharma EEIG*
- SwedenORENCIA 125 mg Injektionsvätska, lösning i förfylld injektionspennaBristol-Myers Squibb Pharma EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Orencia
- Liechtenstein · Orencia
- Norway · Orencia
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e47d19a7-d0b3-4040-bf28-462f01918c73 GET /v1/drugs/e47d19a7-d0b3-4040-bf28-462f01918c73?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "125",
"substance": "ABATACEPT",
"productndc": "0003-2188",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA125118",
"marketing_category": "BLA"
}See everything about abatacept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.